Mundipharma investing S$100m over 5 years in Tuas plant
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
MUNDIPHARMA will invest S$100 million in Singapore over the next five years, with a portion of this going into setting up a facility to make and distribute its range of Betadine antiseptics as well as conduct research and development (R&D).
To be operational by January 2018, the 7,300 sq ft consumer health hub in Tuas is part of the company's wider plans to develop its emerging-markets businesses; this will be its first facility manufacturing consumer and over-the-counter (OTC) products in emerging markets and the largest for Betadine, which is used to prevent and treat infections.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
